Evidence based on real world data of metastatic castration resistant prostate cancer (mCRPC) patients from the Nordic countries is sparse, and insight into the current treatment practice (especially patient level information on drug utilization and patient characteristics) is lacking. This retrospective registry-based real-world evidence (RWE) study intends to provide information on mCRPC patient characteristics, current treatment practice and outcomes in Finland.
